CBD for IBS and irritable bowel: what studies say about cannabidiol and the microbiome

The question in the title has a short answer that most CBD-related sites won't like. In the European PMC database, there is exactly one randomized clinical trial of CBD in patients with irritable bowel syndrome. It involved 32 women and showed no difference compared to placebo. The rest of the material that usually accompanies this term consists of receptors described in physiology textbooks, mice with induced colitis, and trials with cannabis in Crohn's disease. None of these things provide evidence that CBD alleviates IBS. Below you will find what exactly was checked, what the result was, and what gastroenterology has to offer instead.

KEY INFORMATION
• The only randomized trial of CBD in IBS involved 32 women and showed no difference compared to placebo (van Orten-Luiten et al., Cannabis and Cannabinoid Research, 2022).
• The microbiome in humans after four weeks of CBD did not change in a measurable way (Ewell et al., 2026). Reports of microbiota remodeling come from mice.
• The low FODMAP diet, psychotherapy, and antispasmodic medications have thousands of patients behind them in randomized studies.
• Blood in stool, weight loss, anemia, and the onset of symptoms after the age of 50 require diagnostics.

Is there a clinical trial of CBD for irritable bowel syndrome?

There is one. The van Orten-Luiten team published a randomized, double-blind, placebo-controlled crossover trial in 2022 in Cannabis and Cannabinoid Research. Thirty-two women with IBS chewed gum containing 50 mg of CBD as needed for pain, up to six doses per day. At the group level, there was no difference in pain intensity compared to placebo.

This is a negative result, and it's worth looking at the details. Participants rated their pain on a visual analog scale, and quality of life was assessed using the IBS-36 questionnaire. Authors They noted very high variability both within and between individuals, a lack of signal that women reached for gum according to symptom severity, and consumption lower than expected. Their own interpretation of the latter is ruthless: the perceived benefit generally did not outweigh the practical hassle of chewing gum all day.

Another trial from 2011, published in Gastroenterology by Wong and Camilleri's team, is sometimes cited. Seventy-five patients with IBS received a single dose of dronabinol or placebo, and researchers measured colonic sensitivity and motility in a laboratory setting. Dronabinol is a synthetic equivalent of THC, not cannabidiol, the dose was single, and the endpoint was fasting motility, not patient well-being after several weeks. This work says nothing about the efficacy of CBD in daily use.

Moreover, the database is empty. There is no phase 3 trial, no meta-analysis, not even a second randomized study that could be compared with the first. One study on 32 subjects with a negative result is too little to recommend anything, and at the same time too little to definitively close the topic.

Why are cannabinoid receptors in the intestines not evidence?

Because the presence of a receptor indicates where a molecule could act, not whether a patient will feel better. CB1 and CB2 receptors are indeed present in the enteric nervous system and in immune cells of the mucosa. This is anatomy and physiology, described decades ago, not the result of anyone's treatment.

Review Brierley i in. (Nature Reviews Gastroenterology and Hepatology, 2023), prepared by a team of recognized researchers in this field, states cautiously: the endocannabinoid system is a logical molecular target for visceral pain in IBS, and substances that utilize this target have been described as candidates in development. A candidate is not a drug with proven efficacy.

The history of pharmacotherapy for IBS is, in fact, a graveyard of good molecular targets. Reverse agonists of the CB1 receptor provided a reasonable mechanistic justification for the constipation type, but ended up as a source of gastrointestinal adverse effects described in a separate meta-analysis. The road from receptor to clinical benefit can be long and often leads nowhere.

Similarly, the argument from inflammatory bowel diseases does not hold. Crohn's disease and ulcerative colitis involve inflammation of the intestinal wall, which is simply absent in IBS, as IBS is a disorder of gut-brain interactions. Moreover, trials in these diseases most often concerned THC-containing preparations and showed improvement in well-being and symptom severity, not mucosal healing. Transferring such results to IBS would be a double misuse.

Does CBD change the gut microbiome in humans?

The only randomized study measuring this in humans showed no changes. Sixteen overweight adults took 30 mg of CBD twice daily or placebo for four weeks in a double-blind design. The composition of the fecal microbiota after the intervention did not differ significantly between groups.

This is a pilot study Ewella i in. (Cannabis and Cannabinoid Research, 2026), on a small sample and in individuals without IBS, so it does not resolve the issue in the other direction. However, it does clarify something else: there are currently no human data on which to base an opinion about CBD remodeling the microbiome.

So where do these statements come from on the internet? From rodents. The studies that usually back such claims are research on mice: one describes the remodeling of the microbiota that promotes exercise endurance in mice, while another measures the gut microbiome profile after an intraperitoneal injection of cannabidiol in a mouse model. Note the method of administration in this second case. An injection into the abdominal cavity is not the same as swallowing a drop of oil.

Two additional caveats. The microbiota of mice differs from that of humans to such an extent that transferring results is never automatic, and chemically induced intestinal inflammation models in animals do not replicate IBS, which is not an inflammation. And the simplest point: not a single study on the microbiome after CBD in patients diagnosed with irritable bowel syndrome has been published so far.

What has proven effectiveness for IBS?

Several things, and all of them have a significantly stronger basis than cannabidiol. The guidelines from the British Society of Gastroenterology from 2021 and the guidelines from the American College of Gastroenterology from the same year rank them based on meta-analyses, not mechanisms.

Two practical notes regarding this table. The low FODMAP diet is not a lifelong diet: it is listed in the guidelines as a time-limited trial with a reintroduction phase, best conducted with a dietitian, as restrictive elimination diets carry their own risks. Rifaximin pertains to the non-constipated form and is a prescription medication, and the difference compared to placebo, although real, is approximately nine percentage points.

Which intestinal symptoms require diagnostics rather than supplements?

There are symptoms for which no supplementation is the appropriate first response, as they may indicate an organic disease. Gastroenterological guidelines refer to them as alarm symptoms and treat them as indications for urgent medical evaluation, regardless of how much the presentation resembles irritable bowel syndrome.

• Krew w stolcu lub czarne, smoliste stolce.
• Unintentional weight loss.
• Anemia, especially from iron deficiency.
• Onset of symptoms after the age of 50.
• Symptoms that awaken at night, including nocturnal diarrhea.
• Colon cancer or inflammatory bowel disease in close family.
• Palpable resistance in the abdominal cavity or fever.

Even without alarm symptoms, diagnostics make sense. Wytyczne American College of Gastroenterology (2021) They recommend diagnosing IBS with a positive strategy, based on symptom criteria, rather than by simply excluding everything else. For the diarrhea-predominant form, they recommend serological tests for celiac disease and measuring calprotectin in stool to differentiate IBS from inflammatory bowel disease.

This is the most serious accusation against self-administering supplements. A few months of taking oil and observing whether it helps is a few months during which celiac disease, inflammatory bowel disease, or changes in the colon remain undiagnosed. Stool testing and blood sampling take less time than one such trial.

Can CBD be harmful with IBS?

Cannabidiol is not a neutral substance and has a paradoxical profile of side effects in gastrointestinal disorders. Diarrhea is one of the more frequently reported issues, which is an obvious problem in the case of diarrhea-predominant IBS.

A meta-analysis of nine randomized studies in patients with epilepsy, Fazlollahi i in. (JAMA Network Open, 2023), showed that CBD was associated with a higher risk of serious side effects and treatment discontinuation compared to the control group. It is important to note that this involved therapeutic doses on the order of several milligrams per kilogram of body weight, significantly higher than those found in over-the-counter oils. However, the direction of the signal remains the same.

Separately, it is important to mention the carrier. MCT oil, in which cannabidiol is most often dissolved, can loosen stools on its own at larger doses, regardless of what is dissolved in it. With irritable bowel syndrome, it is easy to attribute the effect to the wrong substance.

There is also the interaction with medications. CBD is metabolized by the same cytochrome P450 enzymes as most prescription drugs. A systematic review Nachnaniego i in. (Frontiers in Pharmacology, 2024) gathered 31 documented cases where cannabinoids altered the pharmacokinetics of medications or caused adverse events, involving sixteen substances with a narrow therapeutic index. If you are taking anything regularly, inform your doctor about supplementation before starting it. You can find more about the principles of taking it in the post CBD Dosage.

Frequently Asked Questions

Does CBD help with irritable bowel syndrome?

As of today, there is no evidence for this. The only randomized clinical trial involved 32 women chewing gum with 50 mg of CBD as needed for pain and did not show a difference compared to placebo at the group level (van Orten-Luiten et al., Cannabis and Cannabinoid Research, 2022). The authors themselves stated that studies with a different design are needed.

Does CBD change the human gut microbiome?

The only randomized study measuring the microbiome in humans showed no changes. Sixteen adults took 30 mg of CBD twice daily for four weeks, and the composition of the fecal microbiota did not differ significantly from placebo (Ewell et al., 2026). Claims about microbiome remodeling come from studies on mice.

Do studies on cannabis in Crohn's disease say anything about IBS?

No, because these are separate diseases. Crohn's disease and ulcerative colitis involve inflammation of the intestinal wall, which is not present in IBS. Trials in these diseases most often concerned THC preparations and measured well-being, not the healing of the mucous membrane.

How much CBD should I take for IBS?

There is no established dosage because there are no studies that would determine it. The only protocol tested in a randomized trial for IBS was 50 mg as needed for pain up to six doses per day, which did not outperform placebo. Providing specific milligrams as recommendations is not currently supported by clinical data.

Can CBD worsen diarrhea?

Yes, diarrhea is one of the more common side effects in clinical trials. In a meta-analysis of nine trials involving patients with epilepsy, cannabidiol was associated with a higher risk of treatment discontinuation due to adverse effects (Fazlollahi et al., JAMA Network Open, 2023). MCT oil used as a carrier can also loosen stools.

What should you start with if IBS is suspected?

From the diagnosis made by a doctor. The guidelines from the American College of Gastroenterology recommend testing for celiac disease in the diarrhea form and measuring calprotectin in the stool to rule out non-specific inflammatory bowel disease (Lacy et al., 2021). Only then does the low FODMAP diet and other interventions with proven effectiveness come into play.

If you still want to try cannabidiol for other ailments, fully aware that there is a lack of evidence for its effectiveness in IBS, you can find the assortment in the section oils.

This article is for informational and educational purposes and does not constitute medical advice. Before starting to use cannabis or CBD for therapeutic purposes, consult a doctor, especially if you are taking other medications, are pregnant, or breastfeeding.

Author: Michał Waluk · Opublikowano: 2026-06-22 · Aktualizacja: 2026-08-08